TNYA - Tenaya Market Cap to Sales Volume

Corporate company logo of Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics generates revenue based on the commercial implementation of gene therapy to combat heart failure. Unique patents on gene delivery methods create significant barriers to entry for competitors, as evidenced by the price-to-sales ratio, which is currently fixed at 24.50. Stringent FDA regulations and colossal R&D expenditures render this moat virtually insurmountable.

TNYA: Tenaya Therapeutics P/S Multiple 05/08/2026 - 11/17/2026

Analytical breakdowns for tenayatherapeutics.com (TNYA)

- share price and consensus valuation forecast:
- market capitalization statistics:
Fundamental company analysis:Tenaya Therapeutics Inc - TNYA
Finished products of Tenaya Therapeutics

Tenaya Therapeutics specializes in developing innovative gene therapies for the treatment of hereditary heart pathologies, which drives the high value of its intellectual assets. An analysis of the company's P/S ratio allows for the correlation of market capitalization with annual revenue, determining the degree of overpayment for the business and helping investors timely identify zones of overvaluation or undervaluation of the asset before making a purchase decision.